Ironwood Pharmaceuticals, Inc.
NASDAQ: IRWD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Thomas A. McCourt
- Employees
- 253
- Headquarters
- Boston, United States
- IPO year
- 2010
- Market cap
- $643.6M
- Website
- https://www.ironwoodpharma.com
Loading IRWD…
Loading profile data…Frequently asked questions about IRWD
What does Ironwood Pharmaceuticals, Inc. (IRWD) do?
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irr...
Where does IRWD trade?
Ironwood Pharmaceuticals, Inc. (IRWD) trades on the NASDAQ Global Select.
What sector is IRWD in?
Ironwood Pharmaceuticals, Inc. (IRWD) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Ironwood Pharmaceuticals, Inc.?
Thomas A. McCourt is the chief executive officer of Ironwood Pharmaceuticals, Inc. (IRWD).
Where is Ironwood Pharmaceuticals, Inc. headquartered?
Ironwood Pharmaceuticals, Inc. is headquartered in United States.
Does IRWD pay a dividend?
Ironwood Pharmaceuticals, Inc. (IRWD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IRWD go public?
Ironwood Pharmaceuticals, Inc. (IRWD) completed its initial public offering in 2010.